Trial Profile

Randomized controlled study comparing AEZS-108 with doxorubicin as second line therapy for locally advanced, recurrent or metastatic endometrial cancer

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 27 Dec 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Zoptarelin doxorubicin (Primary) ; Doxorubicin
Indications Adenocarcinoma; Endometrial cancer
Focus Registrational; Therapeutic Use
Acronyms ZoptEC
Sponsors AEterna Zentaris Inc

Most Recent Events

09 Dec 2022 Results assessing dostarlimab (n = 92) efficacy and safety from the single-arm GARNET (NCT02715284) trial compared with doxorubicin ((n = 233) from ZoptEC (NCT01767155) published in the Oncologist
05 Jun 2018 Results presented at the 54th Annual Meeting of the American Society of Clinical Oncology
01 May 2017 Results published in an Aeterna Zentaris media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com